transient receptor potential cation channel subfamily M member 4Genealiases: EKVP6 · LTrpC4 · PFHB1B · TRPM4B · hTRPM4
Q-omics provides the consensus-scored TRPM4 profile across patient tissues and cancer cell-line models. TRPM4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRPM4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TRPM4 protein abundance shows 18,612 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UVM, KIRC, and UCEC as cancer lineages where TRPM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM4 survival associations across molecular data types. TRPM4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM4 RNA expression–survival associations across cancer types. High TRPM4 expression shows unfavorable associations in UVM, ACC, LGG and THCA, but favorable associations in HNSC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRPM4 RNA expression.
This table summarizes TRPM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRPM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM4 shows lower tumor expression in KIRC, COAD and THCA and higher tumor expression in HNSC, LIHC and STAD. The KIRC box plot shows higher TRPM4 RNA expression in normal versus tumor tissue (log2 FC = −1.136, t-test p < 0.001).
This table shows molecular features associated with TRPM4 in patient tissues and cancer cell lines. In patient samples, TRPM4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
